A/S, a global healthcare company specializing in diabetes care and other chronic conditions, has been at the forefront of the rapidly expanding GLP-1 market. With a market capitalization of $376.79 ...

J.P. Morgan analyst Richard Vosser maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of ...

We recently compiled a list of the 12 Best Blue Chip Stocks to Buy Under $100. In this article, we are going to take a look ...

In an important regulatory win for Denmark’s Novo Nordisk, the US Food and Drug Administration (FDA) yesterday approved ...

An analyst thinks he has cracked the code on why highflying Eli Lilly missed two quarters of Wall Street projections.

The term "blue chip" originated from poker, where blue chips were the highest denomination of chips used in the game.

As more United States drug price changes have come to light this month, it remains clear that companies are tamping down ...

Plus: How AI propelled Nvidia up the list and other insights from this year's survey of corporate reputations.

With new drug development, a significant increase in sales, and high potential with Mounjaro and Zepbound, here’s what we think of Eli Lilly’s stock ...

Discover the top genomics startups revolutionizing genome sequencing technologies to enhance disease prevention and treatment ...

The Danish Embassy in Thailand, under the leadership of H.E. Mr. Danny Annan, Ambassador of Denmark to Thailand and Cambodia, ...

The Food and Drug Administration approved Novo Nordisk’s Ozempic as the first GLP-1 treatment option for people with type 2 ...